Eight-Week Phase 2 Study Comparing VSJ-110 Ophthalmic Solution to Placebo for Treating Dry Eye

What this Trial Is About

Researchers are studying the safety and effectiveness of VSJ-110, an eye drop solution, compared to a placebo in treating dry eye. This phase 2 clinical trial aims to provide important information about how well VSJ-110 works and how safe it is for people with dry eye over an eight-week period. The study is randomized and double-masked, meaning neither participants nor researchers know who receives the treatment or placebo during the trial. Participants will be randomly assigned to receive either the VSJ-110 ophthalmic solution or a placebo solution. Both treatments are delivered as eye drops, and the study lasts for eight weeks. The trial is designed to closely monitor the participants response to treatment and any side effects that may occur during this time. Throughout the study, participants will attend scheduled visits where various assessments will be performed. These include measuring corneal staining, which shows eye surface damage, and performing Schirmers Tear Test to evaluate tear production. Participants will also report their eye dryness using a visual scale. The research team will monitor safety and collect data to evaluate the outcomes over the full eight weeks of treatment.

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye